Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study
Acta Dermato-Venereologica · 2025
DOI: 10.2340/actadv.v105.42275 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Laura Calabrese und 17 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy; Institute of Dermatology, Catholic Un…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Dermatologic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Tralokinumab is a monoclonal antibody selectively targeting IL-13, approved for moderate-to-severe atopic dermatitis (AD), for which real-world data are scarce. This prospective, observational, multicentric study aimed to assess the long-term effectiveness and safety of tralokinumab in patients with AD in a real-world setting. Primary outcomes included 50%, 75%, and 90% improvement in Eczema Area and Severity Index score (EASI50, EASI75, EASI90, respectively) and improvements in Dermatology Life Quality Index (DLQI) at 1 year. A total of 136 patients with AD were enrolled in the study; data at 1-year follow-up were available for 111 patients. After 1 year, 68.5% and 33.3% of patients achieved an EASI75 and EASI90, respectively. A significantly higher percentage of patients with than without foot involvement achieved EASI50 (p = 0.009) and EASI75 (p = 0.022). Similarly, hand involvement was significantly associated with higher EASI50 response (p = 0.005). Median DLQI score decreased from 9.00 (interquartile range (IQR): 6.00, 13.75) to 1.00 (IQR: 0.00, 4.00) after 1 year of treatment. Adverse events included blepharitis (n = 10), conjunctivitis (n = 6), and injection-site reactions (n = 2). Tralokinumab can be an effective and safe treatment for patients with moderate-to-severe AD. Involvement of certain body areas, such as hands and feet, might positively predict a clinical response to tralokinumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy; Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy. laura.calabrese@unisi.it.
- Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.
- Cabinet médical, Saint-Maur-des-Fossés, France; Department of Dermatology, Hôpital d'Instruction des Armées Begin, Saint Mandé, France.
- Department of Dermatology, Centre Hospitalier du Havre, Le Havre, France.
- Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France.
- Dermatology and clinical Immunology unit, Antony Hospital, Antony, France.
Zitieren
APA
Calabrese, L., Cinotti, E., D'Onghia, M., Cartocci, A., Rubegni, P., Maccari, F., Boulard, C., Reguiai, Z., Becherel, P. A., Jacobzone, C., Begon, E., Fite, C., Walls, B., Liegeon, A. L., Parier, J., Chaby, G., Perrot, J. L., & Omcci Group (2025). Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.42275
Vancouver
Calabrese L, Cinotti E, D'Onghia M, Cartocci A, Rubegni P, Maccari F, et al. Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.42275
BibTeX
@article{Calabrese2025,
author = {Calabrese, Laura and Cinotti, Elisa and D'Onghia, Martina and Cartocci, Alessandra and Rubegni, Pietro and Maccari, François and Boulard, Claire and Reguiai, Ziad and Becherel, Pierre-André and Jacobzone, Caroline and Begon, Edouard and Fite, Charlotte and Walls, Beatrice and Liegeon, Anne Laure and Parier, Josiane and Chaby, Guillaume and Perrot, Jean-Luc and Omcci Group, Omcci Group},
title = {Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study},
journal = {Acta Dermato-Venereologica},
year = {2025},
doi = {10.2340/actadv.v105.42275}
}
EUVIMED